A New Chemotherapy Regimen for Treatment of Hodgkin's Disease Associated with Minimal Genotoxicity

References

• DeVita V. T., Serpick A. A., Carbone P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Intern. Med. 1970; 73: 881–895
   PubMed Web of Science ®Google Scholar
• Fuller L. M., Hagemeister F. B. Hodgkin's disease in adults: stage I and II. Hodgkin's Disease and Non-Hodgkin 's Lymphomas in Adults and Children, L. M. Fuller, et al. Raven Press, New York 1988; 203–229
   Google Scholar
• Longo D. L., Young R. C., Wesley M., et al. Twenty years of MOPP therapy for Hodgkin's disease. J. Clin. Oncot. 1986; 4: 1295–1306
   PubMed Web of Science ®Google Scholar
• da Cunha M. F., Meistrich M. L., Fuller L. M., et al. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. J. Clin. Oncol. 1984; 2: 571–577
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Larsen S. O. Incidence of acute nonlymphocytic leukemia, preleukemia and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N. Engl. J. Med. 1982; 307: 965–971
   PubMed Web of Science ®Google Scholar
• Valagussa P., Santoro A., Fossati-Bellani F., et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J. Clin. Oncol. 1986; 4: 830–837
   PubMed Web of Science ®Google Scholar
• Sen P., Bailey N. M., Hagemeister F. B., et al. Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential. Cancer Res 1990; 50: 558–562
   PubMed Web of Science ®Google Scholar
• Raposa T., Varkonyi J. The relationship between sister chromatid exchange induction and leukemogenicity of different cytostatics. Cancer Detect. Prev. 1987; 10: 141–151
   PubMedGoogle Scholar
• Clare M. G., Blain E., Taylor J. H. Eur. J. Cancer Clin. Oncol. 1982a; 18: 533–544, Sister chromatid exchanges in human lymphocytes treated with combinations of cytotoxic drugs.
   PubMedGoogle Scholar
• Hagemeister F. B., Cabanillas F., Velasquez W. S., et al. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin. Oncol. 1990; 17(Supplement 10)34–40
   PubMedGoogle Scholar
• Hagemeister F. B., Fuller L., LcLaughlin P., et al (1991) NOVP and radiotherapy for early-staged Hodgkin's disease: Interim analysis. Proceedings of the Second International Symposium on Hodgkin's disease. 1991. Recent Advances in Basic and Clinical Research, CologneGermany
   Google Scholar
• Fuller L. M., Hagemeister F. B., North L. B., et al. The adjuvant role of two cycles of MOPP and los-dose lung irradiation in stage Ia through IIB Hodgkin's disease: Preliminary results. Intl. J. Rad. Oncol. Biol. Phys. 1988; 14: 683–692
   PubMed Web of Science ®Google Scholar
• Rogers R. W., Fuller L. M., Hagemeister F. B., et al. Reassessment of prognostic factors in stage IIIA and IIIB Hodgkin's disease treated with MOPP and radiotherapy. Cancer 1981; 47: 2196–2203
   PubMed Web of Science ®Google Scholar
• Waters M. D., Garrett N. E., Covone-de Serres C. M., . Genetic toxicity of some known or suspected human carcinogens. Chemical Mutagens: Principles and Methods for their Detection, F. J. de, et al. Plenum Press, New York 1983; vol. 8: 261–341, Serres (Ed.)
   Google Scholar
• Hsu T. C., Spitz M. R., Schantz S. P. Mutagen sensitivity: A biological marker of cancer susceptibility. Cancer Epidemiol. Biomarkers & Prev. 1991; 1: 83–89
   PubMed Web of Science ®Google Scholar
• Rao C. R. Linear Statistical Inference and Its Applications., 2nd Ed. John Wiley & Sons, New York 1973
   Google Scholar
• Conover W. J. Practical Nonparametric Statistics, 2nd Ed. John Wiley & Sons, New York 1980
   Google Scholar
• McElwain T. J., Toy J., Smith E., et al. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br. J. Cancer 1977; 36: 276–280
   PubMed Web of Science ®Google Scholar
• Hancock B. W. Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. Radiother. Oncol. 1986; 7: 215–221
   PubMed Web of Science ®Google Scholar
• McKendrick J. J., Mead G. M., Sweetenham J., et al. ChlVPP chemotherapy in advanced Hodgkin's disease. Eur. J. Cancer Clin. Oncol. 1989; 25: 557–561
   PubMedGoogle Scholar
• Druker B. J., Rosenthal D. S., Canellos G. P. Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease. Cancer 1989; 63: 1060–1064
   PubMed Web of Science ®Google Scholar
• Selby P., Patel P., Milan S., et al. ChlVPP combination chemotherapy for Hodgkin's disease: long term results. Br. J. Cancer 1990; 62: 279–285
   PubMed Web of Science ®Google Scholar
• Hancock B. W., Hudson G. V., Hudson B. V., et al. British National Lymphoma Investigation randomized study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran, substituted for mustine) in advanced Hodgkin's disease—long-term results. Br. J. Cancer 1991; 63: 579–582
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. Overall Evaluations of Carcinogenicity. An updating of IARC Monographs, Vols. 1–42. IARC Monographs on the Evaluation of the Carcinogenic Risks of Chemicals to Humans. International Agency for Research on Cancer. 1987
   Google Scholar
• Bonadonna G., Valagussa P., Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann. Intern. Med. 1986; 104: 739–746
   PubMed Web of Science ®Google Scholar
• Santoro A., Bonadonna G., Valagussa P., et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J. Clin. Oncol. 1987; 5: 27–37
   PubMed Web of Science ®Google Scholar
• Valagussa P., Santoro A., Boracchi P., et al. 9-Year results of two randomized studies with MOPP and ABVD in Hodgkin's disease (HD): multiple regression analysis. Proc. Am. Soc. Clin. Oncol. 1989; 8: 250
   Google Scholar
• Valagussa P., Santoro A., Bellani F. F., et al. Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. Blood 1982; 59: 488494
   Google Scholar
• Eghbali H., Bonichon F., David B., et al. Combination of ABVD and radiotherapy in early stages of Hodgkin's disease: analysis of a series of 94 patients. Radiother. Oncol. 1990; 18: 127–136
   PubMed Web of Science ®Google Scholar
• Canellos G. P. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?. Semin. Oncol. 1990; 17(Supplement 2)2–6
   PubMedGoogle Scholar
• Meistrich M. L., Wilson E., Hagemeister F. B., et al (1991) Recovery of sperm production following a new chemotherapy regimen for Hodgkin's disease. Proceedings of Am. Soc. Androl. 1991. MontrealCanada, 57, Supplement
   Google Scholar
• Brown T., Dawson A. A., Bennett B., et al. The effects of four drug regimens on sister chromatid exchange frequency in patients with lymphomas. Cancer Genet. Cytogenet. 1988; 36: 89–102
   PubMed Web of Science ®Google Scholar
• Clare M. G., Jones W. G., Taylor J. H. in vitro. Eur. J. Cancer Clin. Oncol. 1982b; 18: 979–989, Sister chromatid exchanges in human lymphocytes exposed to single cytotoxic drugs in vivo or
   PubMedGoogle Scholar
• Neistadt E. L., Gershanovich M. L., Kolygin B. A., et al. Effect of chemotherapy on the lymph node and bone marrow cell chromosomes in patients with Hodgkin's disease. Neoplasma 1978; 25: 91–94
   PubMed Web of Science ®Google Scholar
• Reeves B. R., Casey G., Harris H., et al. Long-term cytogenetic follow-up study of patients with uveitis treated with chlorambucil. Carcinogenesis 1985; 6: 1615–1619
   PubMed Web of Science ®Google Scholar